We are excited to announce that Advanced Therapies USA 2025 (November 18-19, Philadelphia) will bring together the entire ecosystem of advanced therapies – and we at Anemocyte are proud to be part of it.
This year’s agenda features eight content tracks covering key areas across the cell & gene therapy value chain: manufacturing, supply chain & logistics, pricing & market-access, and recent developments in therapeutic modalities such as cell therapy, gene therapy, gene-edited therapies, stem cells and regenerative medicine
Here are some of the topics we’re especially looking forward to:
- Manufacturing & scale-up: addressing how to cost-effectively manufacture at commercial scale, maintain GMP compliance, optimize processes for consistency and yield.
- Supply chain, logistics & delivery: ensuring the right cold-chain, timely delivery, globally distributed networks that support advanced therapies.
- Pricing, reimbursement & market access: frameworks for how these high-value therapies reach patients, outcome-based agreements, cross-border healthcare, regulatory & payer alignment.
- Therapeutic innovation: deep dives into gene-modified cell therapy, gene editing, stem and regenerative medicine, examining both scientific and commercial leaps.
- Regulatory & strategic challenges: how regulation, quality, safety, global standardization are evolving alongside the new modalities.
At Anemocyte, with our integrated pDNA/mRNA manufacturing platform and global outlook (Italy & USA), we’re ready to engage with these themes, share insights, and explore new collaborations. We look forward to connecting with peers, thought-leaders and potential partners who are driving the next generation of cell and gene therapies.
Want to meet up? Let us know – we’d love to find time to discuss how we can contribute to advancing therapies together.
